CA3089657A1 - Modified lipidated relaxin b chain peptides and their therapeutic use - Google Patents
Modified lipidated relaxin b chain peptides and their therapeutic use Download PDFInfo
- Publication number
- CA3089657A1 CA3089657A1 CA3089657A CA3089657A CA3089657A1 CA 3089657 A1 CA3089657 A1 CA 3089657A1 CA 3089657 A CA3089657 A CA 3089657A CA 3089657 A CA3089657 A CA 3089657A CA 3089657 A1 CA3089657 A1 CA 3089657A1
- Authority
- CA
- Canada
- Prior art keywords
- ttds
- group
- palm
- lysine
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305094 | 2018-01-31 | ||
| EP18305094.7 | 2018-01-31 | ||
| PCT/EP2019/052298 WO2019149782A1 (en) | 2018-01-31 | 2019-01-30 | Modified lipidated relaxin b chain peptides and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3089657A1 true CA3089657A1 (en) | 2019-08-08 |
Family
ID=61223862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3089657A Pending CA3089657A1 (en) | 2018-01-31 | 2019-01-30 | Modified lipidated relaxin b chain peptides and their therapeutic use |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10961295B2 (enExample) |
| EP (1) | EP3746467B1 (enExample) |
| JP (1) | JP7295871B2 (enExample) |
| KR (1) | KR102755938B1 (enExample) |
| CN (1) | CN111770934B (enExample) |
| AR (1) | AR114325A1 (enExample) |
| AU (1) | AU2019214358B2 (enExample) |
| BR (1) | BR112020014834A2 (enExample) |
| CA (1) | CA3089657A1 (enExample) |
| CO (1) | CO2020008308A2 (enExample) |
| DK (1) | DK3746467T3 (enExample) |
| ES (1) | ES3058633T3 (enExample) |
| FI (1) | FI3746467T3 (enExample) |
| HR (1) | HRP20260016T1 (enExample) |
| IL (2) | IL316406A (enExample) |
| LT (1) | LT3746467T (enExample) |
| MA (1) | MA52994A (enExample) |
| MX (1) | MX2020008096A (enExample) |
| MY (1) | MY199821A (enExample) |
| NZ (1) | NZ766762A (enExample) |
| PH (1) | PH12020551118A1 (enExample) |
| PL (1) | PL3746467T3 (enExample) |
| PT (1) | PT3746467T (enExample) |
| RS (1) | RS67606B1 (enExample) |
| SG (1) | SG11202006903WA (enExample) |
| SI (1) | SI3746467T1 (enExample) |
| TW (1) | TWI763972B (enExample) |
| UY (1) | UY38069A (enExample) |
| WO (1) | WO2019149782A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20191716A1 (es) | 2017-02-08 | 2019-12-05 | Bristol Myers Squibb Co | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos |
| WO2019149781A1 (en) * | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
| NZ766762A (en) | 2018-01-31 | 2026-03-27 | Sanofi Sa | Modified lipidated relaxin b chain peptides and their therapeutic use |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| AU2022334113A1 (en) * | 2021-08-23 | 2024-03-14 | River 2 Renal Corp. | Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| CN118510536A (zh) | 2021-11-11 | 2024-08-16 | 泰克托尼治疗股份有限公司 | 松弛素-2融合蛋白类似物及其使用方法 |
| CN115998842B (zh) * | 2022-09-02 | 2025-08-26 | 郑州大学第一附属医院 | 一种逆转肝星形细胞激活的仿生纳米药物及其应用 |
| AU2024270919A1 (en) | 2023-05-18 | 2026-01-15 | Tectonic Operating Company, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
| KR20250054870A (ko) * | 2023-10-16 | 2025-04-24 | (주)케어젠 | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102348723A (zh) * | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| EP2460527A1 (en) * | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| TW201315739A (zh) * | 2011-07-01 | 2013-04-16 | 拜耳智慧財產有限公司 | 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途 |
| RU2014103288A (ru) * | 2011-07-01 | 2015-08-10 | Байер Интеллектчуал Проперти Гмбх | Слитые полипептиды релаксина и их применение |
| JP6276690B2 (ja) * | 2011-08-04 | 2018-02-07 | ファリス バイオテック ゲーエムベーハー | ヒトリラキシン−２を調製する方法 |
| WO2013177529A1 (en) * | 2012-05-24 | 2013-11-28 | Angion Biomedica Corp. | Relaxin-like compounds and uses thereof |
| JP6822839B2 (ja) | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
| EP3131925B1 (en) | 2014-04-17 | 2020-02-19 | The Florey Institute of Neuroscience and Mental Health | Modified relaxin b chain peptides |
| JP2017513875A (ja) * | 2014-04-22 | 2017-06-01 | ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 分枝状アミノ酸プローブを有するペプチド類似体 |
| PE20191716A1 (es) * | 2017-02-08 | 2019-12-05 | Bristol Myers Squibb Co | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos |
| TW201934572A (zh) | 2018-01-31 | 2019-09-01 | 法商賽諾菲公司 | 經修飾之鬆弛素ｂ鏈胜肽及其治療用途 |
| WO2019149781A1 (en) * | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
| NZ766762A (en) | 2018-01-31 | 2026-03-27 | Sanofi Sa | Modified lipidated relaxin b chain peptides and their therapeutic use |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| AU2022334113A1 (en) * | 2021-08-23 | 2024-03-14 | River 2 Renal Corp. | Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions |
-
2019
- 2019-01-30 NZ NZ766762A patent/NZ766762A/en unknown
- 2019-01-30 MY MYPI2020003535A patent/MY199821A/en unknown
- 2019-01-30 WO PCT/EP2019/052298 patent/WO2019149782A1/en not_active Ceased
- 2019-01-30 KR KR1020207020681A patent/KR102755938B1/ko active Active
- 2019-01-30 EP EP19702593.5A patent/EP3746467B1/en active Active
- 2019-01-30 DK DK19702593.5T patent/DK3746467T3/da active
- 2019-01-30 BR BR112020014834-2A patent/BR112020014834A2/pt unknown
- 2019-01-30 LT LTEPPCT/EP2019/052298T patent/LT3746467T/lt unknown
- 2019-01-30 PL PL19702593.5T patent/PL3746467T3/pl unknown
- 2019-01-30 FI FIEP19702593.5T patent/FI3746467T3/fi active
- 2019-01-30 HR HRP20260016TT patent/HRP20260016T1/hr unknown
- 2019-01-30 IL IL316406A patent/IL316406A/en unknown
- 2019-01-30 RS RS20260005A patent/RS67606B1/sr unknown
- 2019-01-30 ES ES19702593T patent/ES3058633T3/es active Active
- 2019-01-30 IL IL276170A patent/IL276170B2/en unknown
- 2019-01-30 JP JP2020541689A patent/JP7295871B2/ja active Active
- 2019-01-30 CN CN201980015588.9A patent/CN111770934B/zh active Active
- 2019-01-30 SI SI201931009T patent/SI3746467T1/sl unknown
- 2019-01-30 CA CA3089657A patent/CA3089657A1/en active Pending
- 2019-01-30 MX MX2020008096A patent/MX2020008096A/es unknown
- 2019-01-30 MA MA052994A patent/MA52994A/fr unknown
- 2019-01-30 AU AU2019214358A patent/AU2019214358B2/en active Active
- 2019-01-30 SG SG11202006903WA patent/SG11202006903WA/en unknown
- 2019-01-30 PT PT197025935T patent/PT3746467T/pt unknown
- 2019-01-31 TW TW108103457A patent/TWI763972B/zh active
- 2019-01-31 US US16/264,643 patent/US10961295B2/en active Active
- 2019-01-31 UY UY38069A patent/UY38069A/es not_active Application Discontinuation
- 2019-01-31 AR ARP190100222A patent/AR114325A1/es unknown
-
2020
- 2020-07-06 CO CONC2020/0008308A patent/CO2020008308A2/es unknown
- 2020-07-22 PH PH12020551118A patent/PH12020551118A1/en unknown
- 2020-10-30 US US17/086,183 patent/US11725036B2/en active Active
-
2023
- 2023-06-26 US US18/341,320 patent/US20240218042A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11725036B2 (en) | Modified lipidated relaxin B chain peptides and their therapeutic use | |
| US10988523B2 (en) | Modified lipidated Relaxin B chain peptides and their therapeutic use | |
| US10988524B2 (en) | Modified relaxin B chain peptides and their therapeutic use | |
| EP4199946B1 (en) | Crf2 receptor agonists and their use in therapy | |
| WO2023161229A1 (en) | Crf2 receptor agonists and their use in therapy | |
| CA3229783A1 (en) | Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions | |
| EP4658674A1 (en) | Gip/glp1/gcg tri-receptor agonists and uses thereof | |
| RU2804702C2 (ru) | Модифицированные липидированные пептиды b-цепи релаксина и их терапевтическое применение | |
| RU2845766C1 (ru) | Агонисты рецептора crf2 и их применение в терапии | |
| HK40112064A (zh) | Crf2受体激动剂及其在治疗中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250124 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250124 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250124 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250321 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250718 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250724 |